Pharma lobbying tightens its grip on the FDA as Trump politics enter the agency
STAT reports that the Trump administration is injecting political priorities into the FDA, signaling a shift from its historically insulated stance. Pharma lobbyists, advisers, and FDA insiders describe more routine interactions about agency decisions, a norm that critics say increases industry influence. Kennedy Jr. has pledged to root out such influence, but sources say the system is now more receptive to political and industry pressures.